Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,601.61
(
0.28%
)
US TECH 100
29,704.40
(
0.58%
)
Dow Jones
51,105.11
(
0.14%
)
Brent Oil
94.76
(
3.72%
)
Bitcoin
71,482.56
(
-2.82%
)
News Focus
News Focus
Post# of 257675
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123046
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197714

Friday, 12/04/2015 10:07:47 AM

Friday, December 04, 2015 10:07:47 AM

Post# of 257675
AMGN submits EU MAA for Humira FoB:

http://finance.yahoo.com/news/amgens-first-biosimilar-marketing-authorization-070000371.html

AMGN submitted a 351(k) BLA to the FDA for this product candidate on 11/25/15 (#msg-118766059).

ABBV’s ancillary patent protection for Humira is not as strong in the EU as it is in the US, so even ABBV expects FoB competition for Humira in the EU after the European CoM matter patent on Humira expires in 2018.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today